Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

CStone and Numab pen immuno-oncology deal

Executive Summary

Numab Therapeutics AG granted CStone Pharmaceuticals Co. Ltd. exclusive rights to develop and sell its immunotherapy candidate ND021 in China, Hong Kong, Macau, Taiwan, South Korea, and Singapore.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register